Transgenic plants as factories for biopharmaceuticals

Area of Science:

• Biotechnology
• Molecular Biology
• Plant Science

Background:

• Plants are a viable and economical source for producing biopharmaceutical proteins and peptides.
• Several companies are actively developing and patenting plant expression systems for biopharmaceutical production.
• Clinical trials are underway for the first wave of plant-derived biopharmaceuticals.

Purpose of the Study:

• To highlight the potential of plant-based systems for biopharmaceutical production.
• To discuss advancements in purification and delivery methods for plant-derived biopharmaceuticals.
• To explore the economic and accessibility benefits of using transgenic plants for medicine production.

Main Methods:

• Utilizing plant expression systems for the synthesis of therapeutic proteins and peptides.
• Developing novel purification techniques, such as oleosin-fusion technology for oil body extraction.
• Investigating direct plant-based delivery (edible vaccines) to bypass purification steps.

Main Results:

• Commercial production of a transgenic plant-derived biopharmaceutical (hirudin) has been achieved.
• Oleosin-fusion technology facilitates extraction and purification via oil bodies.
• Direct ingestion of modified plants offers a potential route for drug delivery and vaccination.

Conclusions:

• Transgenic plants present a scalable and affordable platform for biopharmaceutical manufacturing.
• Innovations in purification and edible delivery enhance the practicality of plant-based biopharmaceuticals.
• This technology promises to increase the availability and reduce the cost of essential medicines, particularly for developing nations.